论文部分内容阅读
TPP美国建议稿中的药品知识产权条款大大突破了TRIPS的最低水平,对药品知识产权的所有核心环节进行了全面整合,大有对全球药品知识产权保护规则重新设制之意。尽管该建议稿也包含了一些公共健康条款,但整体而言,存在严重的失衡。若要消解现有文本对公共健康的巨大压力,需克服一定困难与障碍。于我国而言,TPP提供了借助FTAs选择性植入某些规则,推进秩序转变的范例。我国应基于TRIPS实施近二十年来已经变化了的国际社会情况以及自身情况的改变,合理评估相关条款的风险,于适当时机,择合适路径,参与新一轮规则的制定。
The IPP provisions in the TPP U.S. Proposal drastically broke the minimum TRIPS level and fully integrated all core aspects of pharmaceutical intellectual property, greatly redefining the global drug IPR protection rules. Although this draft proposal also contains some public health articles, overall, there is a serious imbalance. To overcome the enormous pressure on the public health of existing texts, some difficulties and obstacles need to be overcome. For our country, TPP provides an example of selectively imposing certain rules by FTAs to promote the change of order. Based on the TRIPS implementation of the changed international community and its own changes over the past two decades, China should reasonably assess the risks of the relevant provisions and take appropriate paths at appropriate times to participate in the formulation of the new round of rules.